Find and Pitch Jounalists, Get Your Story Covered

Tags: biotech leadership pharma Research & Development research-development

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 7 days ago STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more - 14 days ago STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more - 27 days ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 3 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more - 5 months ago STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions - 5 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 6 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 6 months ago STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more - 6 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a pharma job slowdown, diet drugs boosting GDP, and more - 7 months ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - 7 months ago STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages - 7 months ago STAT+: European regulators tout their accomplishments against pharma’s anticompetitive practices - 8 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - 8 months ago STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 9 months ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - 9 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 9 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 9 months ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - 10 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 10 months ago STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data - 10 months ago STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment - 10 months ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - 10 months ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - 11 months ago STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines - 11 months ago STAT+: Pharmalittle: Pharma trade group slams European Commission proposal; U.S. lawmakers demand FDA explain its approach to shortages - 11 months ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - 11 months ago STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket - 11 months ago STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India - 11 months ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - 11 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 11 months ago STAT+: ‘Missed opportunities’: Why a U.K. government plan to disclose financial ties between pharma and docs may fall short - 11 months ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - 11 months ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - 11 months ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - 12 months ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - 12 months ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - 12 months ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - 12 months ago
2	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: U.K. charities give $36 million to start new drugs for childhood tumors - 14 days ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Is anyone taking the world’s priciest drugs? - 20 days ago Where competition is heating up in pharma - 4 months ago The biggest questions hanging over pharma in 2024 - 8 months ago PharmaVoice 100s: Entrepreneurs - 11 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 28 days ago
5	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	eXmoor pharma’s manufacturing facility receives licence from MHRA - about 1 month ago July/August 2024 - 3 months ago 2024 - 8 months ago
6	Nick Paul Taylor MedTech Dive Top 5 Mario Kart Player. Gaming	UK regulator proposes recognizing overseas medical device approvals - 4 months ago
7	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more - 4 months ago
8	Rupert Hargreaves City A.M. News editor at City AM. London, England JournalismEditing	Covid-19 anniversary: How have GSK and Astrazeneca fared since? - 6 months ago
9	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline - 6 months ago
10	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal - 6 months ago STAT+: Pharmalittle: CRISPR pioneers reflect on future of gene editing; U.K. and pharma reach deal on how NHS pays for drugs - 10 months ago STAT+: U.K., pharma industry strike deal for how the NHS pays for medicines - 10 months ago

Journalists covering UK pharma